Efficacy and safety of margetuximab plus chemotherapy <i>vs.</i> trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study.

Transl Breast Cancer Res · 2022 · PMC11093073 · PMID 38751523

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For the prespecified subgroup analyses, margetuximab plus chemotherapy showed a trend towards greater benefit in prolonging PFS than trastuzumab plus chemotherapy in most of the subgroups ( Figure 4 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.